Parkman Healthcare Partners LLC Decreases Stock Position in Vaxcyte, Inc. (NASDAQ:PCVX)

Parkman Healthcare Partners LLC lessened its stake in Vaxcyte, Inc. (NASDAQ:PCVX) by 10.8% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 116,138 shares of the company’s stock after selling 14,111 shares during the quarter. Parkman Healthcare Partners LLC owned about 0.09% of Vaxcyte worth $9,507,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of PCVX. Wells Fargo & Company MN raised its position in shares of Vaxcyte by 53.7% during the 4th quarter. Wells Fargo & Company MN now owns 72,275 shares of the company’s stock valued at $5,916,000 after acquiring an additional 25,257 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its position in Vaxcyte by 23.1% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 26,428 shares of the company’s stock worth $2,163,000 after buying an additional 4,962 shares during the period. TimesSquare Capital Management LLC increased its position in Vaxcyte by 53.7% in the fourth quarter. TimesSquare Capital Management LLC now owns 413,637 shares of the company’s stock worth $33,860,000 after buying an additional 144,516 shares during the period. Allspring Global Investments Holdings LLC increased its holdings in shares of Vaxcyte by 70.8% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 593,523 shares of the company’s stock valued at $49,418,000 after purchasing an additional 246,049 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in shares of Vaxcyte by 188.4% during the fourth quarter. Smartleaf Asset Management LLC now owns 398 shares of the company’s stock valued at $33,000 after purchasing an additional 260 shares during the period. Hedge funds and other institutional investors own 96.78% of the company’s stock.

Vaxcyte Price Performance

Shares of PCVX stock opened at $30.05 on Wednesday. The stock’s fifty day simple moving average is $44.91 and its 200 day simple moving average is $73.32. The firm has a market cap of $3.88 billion, a price-to-earnings ratio of -6.53 and a beta of 1.27. Vaxcyte, Inc. has a one year low of $27.66 and a one year high of $121.06.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 14th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.02) by ($0.02). During the same quarter last year, the business earned ($0.85) earnings per share. On average, research analysts anticipate that Vaxcyte, Inc. will post -4.21 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Guggenheim reaffirmed a “buy” rating and set a $160.00 target price on shares of Vaxcyte in a report on Wednesday, March 12th. The Goldman Sachs Group lowered their target price on Vaxcyte from $138.00 to $100.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Cantor Fitzgerald began coverage on Vaxcyte in a report on Tuesday, April 22nd. They set an “overweight” rating for the company. Needham & Company LLC restated a “buy” rating and issued a $90.00 target price on shares of Vaxcyte in a report on Tuesday, April 8th. Finally, Bank of America dropped their price target on Vaxcyte from $157.00 to $137.00 and set a “buy” rating on the stock in a research report on Tuesday, April 1st. Nine analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Vaxcyte has a consensus rating of “Buy” and a consensus target price of $136.50.

Insider Activity

In other Vaxcyte news, CFO Andrew Guggenhime sold 8,000 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $83.85, for a total value of $670,800.00. Following the completion of the sale, the chief financial officer now directly owns 109,491 shares in the company, valued at $9,180,820.35. This represents a 6.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 3.10% of the stock is currently owned by insiders.

Vaxcyte Company Profile

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.